NCT03213587

Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Had Failed Prior Platinum Based Chemotherapy

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 51 (estimated)
• Sponsor: Zhejiang Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who failed prior platinum based chemotherapy

Conditions

• Nasopharyngeal Carcinoma

Interventions

Type	Name	Description
DRUG	Apatinib	500 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

Timeline

• Start date: 2017-07-01
• Primary completion: 2020-07-01
• Completion: 2020-07-01
• First posted: 2017-07-11
• Last updated: 2017-07-11

Locations

1 site across 1 country: China